These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20795753)

  • 1. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
    Meuth SG; Bittner S; Ulzheimer JC; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Oct; 24(5):317-30. PubMed ID: 20795753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Rolfes L; Pawlitzki M; Pfeuffer S; Huntemann N; Wiendl H; Ruck T; Meuth SG
    BioDrugs; 2020 Oct; 34(5):587-610. PubMed ID: 32785877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Huntemann N; Rolfes L; Pawlitzki M; Ruck T; Pfeuffer S; Wiendl H; Meuth SG
    Drugs; 2021 Jun; 81(9):1031-1063. PubMed ID: 34086251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.
    Pfeuffer S; Ruck T; Kleinschnitz C; Wiendl H; Meuth SG
    Expert Rev Neurother; 2016 Jun; 16(6):689-700. PubMed ID: 27058174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future treatment approaches to multiple sclerosis.
    Derwenskus J; Lublin FD
    Handb Clin Neurol; 2014; 122():563-77. PubMed ID: 24507535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.
    Bittner S; Wiendl H
    Neurotherapeutics; 2016 Jan; 13(1):4-19. PubMed ID: 26563391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in MS therapeutics: vehicles of hope.
    Fox RJ; Ransohoff RM
    Trends Immunol; 2004 Dec; 25(12):632-6. PubMed ID: 15530830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.
    Kapoor R
    Curr Opin Neurol; 2006 Jun; 19(3):255-9. PubMed ID: 16702831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple sclerosis: potential therapeutic options and update of ongoing studies].
    Wiendl H; Lehmann HC; Hohlfeld R; Hartung HP; Kieseier BC
    Nervenarzt; 2004 Jun; 75(6):536-52. PubMed ID: 15257377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection in multiple sclerosis.
    Karussis D; Grigoriadis S; Polyzoidou E; Grigoriadis N; Slavin S; Abramsky O
    Clin Neurol Neurosurg; 2006 Mar; 108(3):250-4. PubMed ID: 16413962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status.
    Waxman SG
    Nat Clin Pract Neurol; 2008 Mar; 4(3):159-69. PubMed ID: 18227822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Other immunomodulatory therapies in multiple sclerosis.
    Polman CH
    Baillieres Clin Neurol; 1997 Oct; 6(3):511-24. PubMed ID: 10101587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.